RxDoctor Payments Data

Omar Barakat, MD

General Surgery · Houston, TXNPI 1649260969

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $123,035 of the $145,226 with a category attached, or 84.7%. Ipsen Biopharmaceuticals, Inc accounts for 99.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $56,016 and has fallen 99.8% since, to $105 in 2025. Among general surgery clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$145,226in general payments, 2019–2025

Across 124 payments — averaging $1171.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Biopharmaceuticals, Inc$144K
  • Johnson & Johnson$328
  • Tersera Therapeutics LLC$240
  • Boston Scientific$107
  • Angiodynamics, Inc.$105
  • Wound Management Technologies, Inc$77
  • plus $47 from 2 others

What the payments were for

  • Speaking & faculty fees$123,03585%
  • Travel & lodging$18,08212%
  • Food & beverage$4,1103%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ipsen Biopharmaceuticals, Inc108$144,323
Johnson & Johnson3$328
Tersera Therapeutics LLC3$240
Boston Scientific2$107
Angiodynamics, Inc.2$105
Wound Management Technologies, Inc3$77
TELA Bio, Inc.2$32
Axonics, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$145,226 in reported general payments places this provider in the 95th percentile of 61 general surgery providers in Texas.

See all general surgery providers in Texas

Medicare billing

Part B allowed, 2024
$48,873
Medicare patients
86
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ursodiol17$2,511
Tramadol Hcl45$115
Metoclopramide Hcl13$31

Paid to pharmacies, not to this prescriber.

Other general surgery in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →